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Abstract 
Mucopolysaccharidoses (MPS) are a group of inherited metabolic disorders caused by the deficiency of 
lysosomal enzymes necessary for the degradation of glycosaminoglycans (GAGs). Non-degraded GAGs 
accumulate inside the lysosomes and compromise cell function in different tissues and organs. This 
accumulation causes progressive and multisystemic damage, leading to a wide spectrum of clinical 
manifestations, including oral and craniofacial manifestations. This work aims, therefore, to conduct a 
literature review that promotes specific knowledge regarding the oral and craniofacial manifestations of 
MPS. The results converged to a variability of alterations, among them facial dysmorphism, 
macroglossia, lingual protrusion, anterior open bite, dental caries, gingival inflammation, enamel 
hypoplasia, taurodontism, condylar hypoplasia and presence of dentigerouscysts. Preventive and 
interceptive actions in oral health are used as a means of improving oral hygiene and reducing oral 
problems. Finally, there is a need for improvement in comprehensive care for patients with MPS. 
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1. Introduction 
Lysosomal overload diseases (LOD) are a heterogeneous group of rare and progressive 
pathologies characterized by impairment of the lysosomal catabolic pathways necessary for 
essential cellular biological processes. Integrated in this group of metabolic disorders are 
mucopolysaccharidoses (MPS), resulting from deficiencies in lysosomal enzymes responsible 
for the degradation of glycosaminoglycans (GAGs) [1, 2]. 
MPS carriers are unable to produce or present any abnormality in these lysosomal hydrolases, 
interrupting the catabolism of GAGs, resulting in their accumulation within the lysosomes. 
This accumulation causes progressive damage and impairs cell function. In addition, when the 
cell no longer has space available, these GAGs are excreted in the urine, which is an important 
parameter for investigating MPS [2, 3]. 
In MPS, the affected physiological processes, in addition to the lysosomal deposit, are (a) 
changes in the pattern of plasma membrane receptors; (b) dysfunctional macrophage with 
accumulation of GAGs; (c) changes in the uptake of cytokines and growth factors; (d) changes 
in the recruitment of circulating cytokines and in the presentation of cytokines to recipients; (e) 
abnormal interactions of the extracellular matrix; and (f) altered cell adhesion [4]. 
In Portugal, MPS have a prevalence of 4.8/100,000 of born individuals. In 2017, the number of 
patients with lysosomal overload pathologies was 256 individuals, 32 of whom had MPS [1, 5]. 
Given the progressive clinical course of the disease, a multidisciplinary approach is needed to 
monitor these patients. Therefore, prevention and immediate intervention is essential to 
maintain health and improve quality of life. In addition, knowledge of oral and craniofacial 
manifestations present in patients with MPS is of crucial importance for the early diagnosis of 
the pathology. The purpose of this literature review is to promote specific knowledge of oral 
and craniofacial changes present in MPS, with a view to the planning and appropriate 
monitoring of these patients. 
 
2. Materials and Methods 
It is a qualitative study of literature review, appropriate for updating knowledge on the 
proposed theme, showing new ideas or scientific trends. Articles in the PubMed databases 
were surveyed, considering the period from 2009 to 2019. 
 ~ 48 ~ 
International Journal of Applied Dental Sciences http://www.oraljournal.com 
In addition, references prior to 2009 and/or indexed in other 
databases were consulted and used as a theoretical 
framework. The indexing terms used were 
“mucopolysaccharidoses and oral manifestations”, 
“mucopolysaccharidoses and craniofacial manifestations” and 
“mucopolysaccharidoses and oral health”. From there, the 
analysis of the theoretical foundation of the studies was 
continued. Finally, there was an assessment of the applied 
methodology, results obtained and discussion. To analyze the 
identified scientific production, specific qualitative and/or 
quantitative techniques of data treatment were not used, 
having analyzed each of the texts individually. Therefore, this 
review was carried out through the analysis of 26 
bibliographic references. 
GAGs are long, unbranched polysaccharide chains, composed 
of repetitions of disaccharides, which are synthesized in the 
Golgi complex. Among the main functions, the attachment to 
the cytokines, the cell surface receptor and to specific proteins 
stands out, in addition to hyaluronic interactions. Except for 
hyaluronic acid, all GAGs are sulfated and linked with a 
protein nucleus - proteoglycan - which is the main component 
of the extracellular matrix. The specific individual units of 
monosaccharides define the GAG subtype, as shown in Table 
1 [4].  
 
Table 1: Subtypes of GAGs. 
 
GAG Composition 
Heparan sulfate Glucosamine and glucuronic or iduronic acid 
Dermatan sulfate N-acetylgalactosamine and iduronic acid 
Chondroitin sulfate N-acetylgalactosamine and glucuronic acid 
Keratan sulfate N-acetylglucosamine and galactose 
Hyaluronic acid N-acetylglucosamine and glucuronic acid 
 
In a healthy cell, GAGs detach from the plasma membrane 
and enter the cell to be degraded in lysosomes. For the 
breakdown of GAGs, there is a series of enzymes that work in 
sequence until the removal of a sugar molecule at one end of 
the chain, such as iduronidase, β-galactosidase 1, arylsulfatase 
B and hyaluronidase. Enzymes play the role of digesting 
degradation products that are toxic to the cell. 
Monosaccharides and inorganic sulfate generated from this 
degradation are transported outside the lysosome [4]. 
MPS are classified into seven large groups according to the 
enzyme deficiency and accumulated GAGs, as shown in 
Table 2. The change in the degradation of GAGs is caused by 
mutations in the genes encoding lysosomal hydrolases. Most 
of these diseases are hereditary conditions with an autosomal 
recessive inheritance pattern, except for MPS II, which 
transmission is associated with the X chromosome. When 
born, MPS patients have a normal phenotype and no signs or 
symptoms, except for MPS VII whose common complication 
is hydrops fetalis - accumulation of interstitial fluid in the 
fetus [2, 4, 6].  
 
Table 2: Types of MPS, with corresponding enzyme deficiencies and accumulated GAGs. 
 
Type Syndrome Enzyme deficiency Accumulated GAGs 
MPS I Hurler-Scheie α-L-iduronidase 
Heparan sulfate 
Dermatan sulfate 
MPS II Hunter Iduronate-2-sulfatase 
Heparan sulfate 
Dermatan sulfate 
MPS III 
Sanfilippo 
A 
B 
C 
D 
E 
Heparan-N-sulfatase 
α-N-acetylglucosaminidase 
Acetyl-CoA-α-glucosaminidase 
N-acetylglucosamine 6-sulfatase 
N-glucosamine-3-O-sulfatase 
Heparan sulfate 
MPS IV 
Morquio 
A 
B 
Galactose 6-sulfatase 
β -galactosidase 1 
Keratan sulfate 
Chondroitin 6-sulfate 
MPS VI Maroteaux-Lamy N-acetylgalactosamine 4-sulfatase (Arilsulfatase B) Dermatan sulfate 
MPS VII Sly β-glucuronidase Heparan sulfateDermatan sulfate 
MPS XI Natowicz Hyaluronidase Hyaluronic acid 
 
Due to the multisystemic nature of the disease, each type of 
MPS has specific traits in its clinical expression according to 
the progression of GAGs accumulation. In general, the 
clinical onset of the disease occurs in early childhood, 
however physical manifestations end up being common to 
most syndromes. Facial dysmorphism, macrocephaly, short 
stature, generalized dysostosis, joint dysplasias, skin 
thickening, cardiorespiratory impairment, 
hepatosplenomegaly, umbilical and inguinal hernias, corneal 
opacification, hearing impairments, delayed motor 
development and, in the most severe forms, cognitive 
impairment and neuropsychiatric disorders are frequent [2, 7]. 
The heterogeneity of these manifestations and the similarity 
with the symptoms associated with other pathologies make 
the diagnosis difficult. Based on clinical suspicion, laboratory 
tests should be performed. First, the quantitative analysis of 
GAGs in urine is used as a guide for the investigation of the 
disease. Thereafter, enzymatic assays are performed to 
confirm the diagnosis [2, 6, 8]. Prenatal diagnosis should be 
considered in cases of family history or gestational signs, 
being performed through the analysis of the enzyme 
deficiency in the amniotic fluid or by chorionic villus biopsy 
[2]. 
There is no cure for these disorders, so early diagnosis is 
essential to provide adequate medical treatment, allowing the 
delay of the development of irreversible sequelae. Nowadays, 
enzyme replacement therapy (ERT) is considered the main 
form of treatment and consists of the replacement of the 
missing enzyme by a recombinant human enzyme, through 
intravenous infusions. These recombinant enzymes simulate 
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the biological effects of the missing one, being captured by 
the cells, and directed to lysosomes. In recent years, this 
therapy has improved the life expectancy of patients.  
However, treatment varies according to the type of MPS, and 
other therapeutic methods are available, such as 
hematopoietic cell transplantation and gene therapy [6, 9, 11]. 
The oral and craniofacial manifestations described in 
individuals with MPS are varied and can have different 
degrees of severity depending on the type of the disease.  
 
3. Craniofacial manifestations 
Facial dysmorphism is common and consists of an anatomical 
malformation of the structures of the face. Some dysmorphic 
characteristics related to patients with MPS are the coarse 
face and thick lips, resulting from the thickening of the soft 
tissues of the face by the accumulation of GAGs. In addition, 
facial skeletal changes were found in conjunction with other 
physical manifestations due to multiple dysostosis. Facial 
asymmetry, high and prominent forehead, high palate, short 
mandibular ramus, and maxillary hypoplasia are 
characteristics frequently mentioned in the literature [10, 12, 17]. 
In patients with MPS, the impact on facial structures can also 
be associated with macroglossia and lingual protrusion. 
Abnormal tongue development can impair chewing and 
phonation, lead to opening of diastemas, in addition to 
breathing difficulties [10, 14, 15, 17, 19]. 
Regarding the radiological findings, it is possible to 
emphasize the changes related to the temporomandibular joint 
(TMJ). In general, the most frequent changes are condylar 
hypoplasia, increased coronoid processes, degenerative 
changes in the eminences and changes in the shape of the 
articular fossa [10, 13, 14, 16, 19, 22]. 
In a clinical study, using computed tomography and magnetic 
resonance imaging, Cavaleiro et al. [10] observed 
characteristics that were not clear in conventional 
radiographs, such as the morphological changes of the 
condylar processes with flattening and condylar erosion, in 
addition to the loss of joint height. They also found an intense 
proliferation of cartilage in the retrodiscal area between the 
condyle and the fossa and anterior disc displacement. 
Symptoms of temporomandibular disorders (TMD) were 
observed in patients with MPS IVA and VI, such as ear pain, 
headaches associated with clicks and crackles in the opening, 
reduced condylar mobility, pain during excursions and pain 
on craniofacial muscle palpation [10, 21]. 
Imaging is also useful when assessing bone quality. 
Trabecular variation like osteoporosis and enlarged medullary 
spaces, cortical thinning and generalized bone rarefactions 
could be seen in patients with MPS types I, II, IV and VI [10, 
13, 22]. 
Hypoplastic condyles and trabecular variation, together with 
macroglossia and tongue protrusion, are identified as the 
cause of severe dental malocclusions. The anterior open bite 
is one of the most recurrent findings, with a high incidence 
among patients with MPS [10,12-17,19, 21]. 
Kantaputra et al. [19] argue that the anterior open bite in 
patients with MPS VI results from a hypoplastic mandibular 
condyle. As an example, two patients who started ERT at an 
early age (before 3 years of age) did not develop anterior open 
bite. Likewise, Almeida-Barros et al. [21] found an anterior 
open bite in all patients with MPS VI who had hypoplastic 
condyles. For Torres et al. [14], condylar hypoplasia added to 
the open bite had implications on the chewing problems 
reported by the patients. 
Among malocclusions, in patients with MPS, the most 
frequent posterior crossbite [10, 14, 15], are class II with 
generalized diastemas [14] and class I with dental crowding [14, 
18]. In addition, some deleterious oral habits were mentioned, 
such as mouth breathing and snoring [10, 13, 16]. 
Also, regarding radiological findings, manifestations such as 
delayed rhizogenesis and dental eruption, impaction of 
deciduous and permanent teeth, in addition to the presence of 
hyperplastic dental follicles compatible with dentigerous cysts 
were reported. In patients with MPS types I, IV, VI and VII, 
the posterior teeth are the most affected [10, 12, 14, 16, 19, 22]. In 
this follow-up, changes in the normal course of tooth eruption 
were also associated with chemotherapy and irradiation in 
patients under preparation for bone marrow transplantation 
[18]. 
 
3.1 Oral manifestations 
Among the oral clinical changes observed in these patients, 
the problems associated with the high incidence of caries and 
periodontal disease were highlighted, marked by the need for 
dental treatment [12, 17, 20, 23]. 
A sample of 30 patients was examined by Ballikaya et al. [13]. 
Clinically, 90% of these patients had dental caries and 90.5% 
had gingival inflammation. The increase in dental caries in 
these patients was related to dry mouth and more acid pH of 
the saliva. In addition, the impact of mental impairment and 
joint and skeletal limitations on these individuals' manual 
dexterity contributed to poor dental hygiene [13]. 
Regarding vulnerability to dental caries, individuals with 
MPS are approximately three times more likely to develop 
caries than healthy individuals. The physical limitations and 
motor impairment of these patients lead to dependence 
concerning daily activities such as oral hygiene, performing 
them inappropriately or infrequently [23]. In contrast and 
reinforcing a causal relationship with the disease, patients 
with MPS with good hygiene and parental involvement also 
had dental caries [17]. 
Regarding periodontal evaluation, patients presented gingival 
inflammation and accumulation of dental calculus due to poor 
oral hygiene [12, 14, 16, 19]. In addition, significant gingival 
hyperplasias were observed in the areas of unerupted teeth [10]. 
Concerning dental morphology changes, anomalies in 
structure, number, size and shape were observed [10, 12, 14, 16, 18-
22, 24, 25]. 
Structural changes in tooth enamel, both in primary and 
permanent dentition, were observed by Khan et al. [24] and Al-
Jawad et al. [25] using synchrotron radiation and electron 
microscopy techniques. In patients with MPS I, abnormalities 
were observed during mineralization of the enamel matrix. 
The presence of a poorly calcified layer between the enamel 
and the dentin, at the amelodentinary junction (ADJ), makes 
the structure in this region weak and susceptible to fractures. 
The enamel is hypoplastic and easily detachable from the 
underlying dentin. This lack of integration in ADJ is 
indicative of the lack of specific sulfatase to remove local 
GAGs from dentinal tubules [24, 25]. 
Significant differences in enamel texture distribution were 
seen in patients with MPS types II and IVA. In a healthy 
enamel, the crystals present in the cusp region are well 
aligned while in a deeper region the crystals are less ordered 
due to the change in configuration in the orientation of the 
prisms towards the ADJ. In individuals with MPS, the 
distribution is characterized by a constant gradation of the 
crystals over the entire thickness of the tooth [24, 25]. 
In clinical examinations, enamel hypoplasia was regularly 
observed in patients with MPS IV [14, 16, 18, 21, 22]. 
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Among the shape anomalies, taurodontism was the most 
recurrent change [12, 13, 19, 22], being common in the first and 
second permanent molars in MPS VII [12, 19]. In addition, it 
showed a high prevalence in individuals with MPS VI, due to 
the accumulation of dermatan sulfate that affects growth 
factors. Another found modification was the presence of 
conoid teeth [10, 18]. 
In relation to number and size anomalies, the presence of 
supernumerary teeth, dental agenesis and microdontia have 
been reported [10, 19, 20, 22]. In patients with MPS I after 
hematopoietic stem cell transplantation, it was observed the 
development of these anomalies, that were related with the 
treatment [22]. 
Changes in pulp chambers and periapical tissues have been 
reported by Kantaputra et al. [12] and Wadenya et al. [18]. 
Among these changes are the broad root spaces, obliterated 
pulp chambers and interrupted root development. 
As for otorhinolaryngological involvement, patients with 
MPS may have an accumulation of GAGs in the upper 
airways and neck. As a result, there is adenotonsillar 
hypertrophy that leads to airway obstruction and obstructive 
sleep apnea syndrome (OSAS), decreasing the life quality of 
these individuals [8, 10]. 
Sinus and lower tract infections are also common, secondary 
to an enlarged amygdala, adenoid and tongue [10, 17]. In 
addition, hearing loss is frequent due to otitis media with 
effusion [8] and earaches related to TMDs [10]. 
 
4. Dental management of patients with 
mucopolysaccharidoses 
Dental management of patients with MPS focuses on 
guidelines for health promotion and prevention of oral 
diseases. The following actions have been reported: dental 
evaluation and prophylaxis every six months, oral hygiene 
instructions, pit and fissure sealants, dietary advice, and 
topical fluoride application [14, 17, 18]. 
The emphasis must be on oral hygiene and on prevention of 
problems that require invasive procedures [10]. In this sense, it 
is essential to educate and motivate patients, but also parents 
and guardians, for good oral hygiene to reduce the incidence 
of caries and gingival inflammation [13, 16, 17]. When there are 
preventive failures, the treatment plan must be formulated 
based on the patient's complaints and his systemic condition 
[15]. 
In the curative treatment of oral and craniofacial changes, care 
is mainly symptomatic. Among interventional procedures are 
restorative treatment [10, 17, 20], endodontic treatment of teeth 
with irreversible pulpitis [20] and extraction of retained 
primary teeth [15]. Complex procedures that require sedation or 
general anesthesia can be at high risk due to the various 
cardiorespiratory problems [10, 13, 20]. 
It is recommended to evaluate mandibular movements to 
identify signs and symptoms of TMD in patients with MPS, 
especially with MPS VI who are most severely affected [21]. In 
addition, orthodontic treatments and prosthetic replacements 
aim, respectively, at adequate control of the eruption 
pathways and the restoration of occlusion with improved 
quality of life [14,18]. 
In the dental treatment of patients with MPS, other factors 
were also considered, such as the individual's degree of 
mental deficiency and difficulty in clear communication, the 
presence of convulsive disorders that impair the care and the 
degree of joint stiffness, which hinder the performance of 
procedures and cause discomfort to the patient. In addition, 
the need for antimicrobial prophylaxis was stressed, as 
patients with MPS are part of a group at high risk for bacterial 
endocarditis [20]. 
In airway obstructions and OSAS due to adenotonsillar 
hypertrophy, patients can benefit from adenotonsillectomy to 
which OSAS improves significantly. However, in some cases 
the obstruction may require endotracheal intubation. In cases 
of hearing loss due to otitis media by effusion, the treatment is 
the insertion of a ventilation tube [8]. 
 
5. Discussion 
According with the literature, studies on oral and craniofacial 
manifestations of MPS patients are still not widespread, being 
most of them clinical case reports. By proceeding to a 
systematic observation of the relationship between oral 
problems acquired by the accumulation of GAGs and the 
proper management of these patients, there are still gaps to be 
filled. With this aim, prospective cohort studies with a control 
group that are based on elucidating possible causal 
relationships between MPS and oral problems may be 
relevant [13], as well as multicenter clinical trials in groups of 
patients with MPS [26].  
The little disclosure about these disorders can also discourage 
professionals in the treatment of these patients, in addition to 
decreasing the chances of an early diagnosis and correct 
referral. It is well known that the comprehensive care of 
patients with MPS is based on multidisciplinary, as well as 
the alignment of communication between the involved 
professionals. Torres et al. [14] warn of the lack of qualified 
professionals to care for these patients who require special 
care. 
The starting point for health promotion in patients with MPS 
is early diagnosis. Family screening for the disease and 
treatment at a young age promotes a significant reduction in 
the accumulation of GAGs and, consequently, in the 
progression of morphological and neurological changes [14, 19]. 
Hematopoietic cell transplant therapy from the umbilical cord, 
for example, modified the course of the disease in a patient 
with MPS II, providing sufficient enzyme activity to alter the 
progression of symptoms and attenuating typical facial 
dysmorphism [14]. 
Knowledge of oral and craniofacial manifestations of MPS is 
also relevant in clinical practice, since when installed, they 
can serve as pathognomonic characteristics of the disease and 
allow referral to the pediatrician in advance [15,19]. In addition, 
the oral assessment must be continued to detect any new 
health impairment [14]. 
This review allows to recognize the role of the dental doctor 
in identifying these changes for diagnosis purposes, but also 
in preventive oral actions and dental intervention that 
minimizes the severity of the established problem and avoids 
undesirable complications [13, 16]. In general, it was observed 
that oral management of a preventive nature has as priority 
the improvement of oral hygiene and non-invasive dental care 
such as dental prophylaxis, periodic evaluations, dietary 
advice, sealing of fissures and the topic application of fluoride 
[14, 17, 18].  
These patients are more vulnerable to oral problems due to the 
limitations imposed by the disease, such as motor and 
cognitive difficulties [23]. From this point of view, the 
maintenance of oral hygiene for these patients is causally 
related to the education and awareness of parents or 
guardians. It is suggested that professionals demonstrate 
brushing techniques, reinforce the need to use fluoridated 
toothpaste, in addition to the use of dental floss to prevent 
caries and gum disease. The patient should also be 
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encouraged to use brushes suitable for his needs. 
The importance of this preventive care is evident in data 
regarding the high levels of dental caries and periodontal 
disease reported in these patients [12, 17, 20, 23]. Dental care 
carried out as soon as possible can help to anticipate the onset 
or worsening of these problems, in addition to providing an 
environment for changing habits in oral health that can be 
perpetuated throughout the patient's life. In this perspective, 
Tatapudi et al. [17] suggested the development of new research 
addressing determinant causes of dental caries in patients with 
MPS having good oral hygiene. 
When interventional treatment in oral and craniofacial 
manifestations becomes necessary, dental treatment strategy 
must consider the general health condition of the patient with 
MPS and attention must be focused on the cardiorespiratory, 
musculoskeletal, and neurological problems presented. In 
addition, the patient's complaints should be evaluated. 
Moreover, Yoon et al. [20] highlight the need for antibiotic 
prophylaxis in some procedures, to prevent endocarditis. 
More complex dental treatments or more aggressive surgeries 
are not recommended, due to the need for sedation or general 
anesthesia, being a life risk for the patient, due to the 
difficulty of clearing the airways and cardiac involvement [10, 
13, 18, 20]. 
The manifestations relevant to TMDs, such as headache and 
pain [10, 21], can affect many of these patients due to common 
TMJ changes. Thus, it is suggested that dental doctors are 
aware of these dysfunctions so that the referral to the TMD 
specialist is carried out. These professionals are prepared for 
advice on controlling symptoms and, therefore, improving the 
patient's quality of life. 
 
6. Conclusions 
The description of oral and craniofacial manifestations in 
patients with MPS is based on the increased specific 
knowledge about the disease. The results and discussions of 
this review corroborate the statement that recognizing these 
changes can help to make an early diagnosis and, therefore, 
prior referral to therapeutic resources and prevention of 
systemic worsening.  
In the dental management of patients with MPS, preventive 
and interceptive actions in oral health aim to improve oral 
hygiene and reduce oral problems to avoid future 
complications. 
The obtained data also allow to suggest new research of a 
prospective character, which systematize the causal 
relationships in oral health, or multicentric research in MPS. 
In addition, the importance of continuing education for health 
professionals and the need to improve care for patients with 
MPS is emphasized, considering the quality of life and 
comprehensiveness of their needs. 
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